Associate Director/Director, Global Clinical Operations at Vor Bio

Boston, Massachusetts, United States

Vor Bio Logo
Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, PharmaceuticalsIndustries

Requirements

  • Experience and knowledge of end-to-end management of clinical trial operations
  • Knowledge of the pharmaceutical industry
  • Understanding of clinical drug development and clinical trials operations

Responsibilities

  • Accountable for delivery of assigned clinical program/studies budget, timelines, and resource management with a focus on quality, including making recommendations and decisions regarding operational strategies to support study and/or program objectives
  • Ensure clinical trials comply with ICH/GCP guidelines, regulations, and company SOPs
  • Develop operational strategy and clinical operations plans to support the execution of the Clinical Development Plan
  • Support the selection, oversight, and management of CROs and other vendors
  • Oversee site feasibility/capability assessments in collaboration with the CRO and cross-functional team
  • Review and provide clinical operations input into relevant clinical documents such as the protocol, investigator brochure, regulatory documents, clinical study reports, and other documents and plans as appropriate
  • Manage the cross-functional team and CRO/vendor(s) related to all aspects of clinical trial operations
  • Assist in forecasting clinical trial material and ancillary supplies
  • Represent Clinical Operations on cross-functional project teams and vendor/CRO operational meetings and ensure compliance with operational standards and procedures
  • Ensure timely review of protocol deviations and assess the impact on study data
  • Represent Vor Biopharma externally to Investigators, site staff, and Key Opinion Leaders
  • Perform and document study level Sponsor Oversight of outsourced clinical activities
  • Communicate study status, cost, and issues to ensure timely decision-making by senior management
  • Oversee/collaborate and contribute to inspection readiness activities that support audits and regulatory inspections related to clinical trial conduct
  • Develop and foster strong, collaborative relationships with key stakeholders both within and external to Vor Biopharma
  • Support program level deliverables/activities

Skills

Clinical Operations
Clinical Trials Management
CRO Management
Vendor Management
Cross-Functional Collaboration
Pharmaceutical Industry
Autoimmune Programs
Clinical Development
Trial Execution
Global Clinical Operations

Vor Bio

Develops targeted therapies for blood cancers

About Vor Bio

Vor Biopharma focuses on developing treatments for blood cancers, particularly Acute Myeloid Leukemia (AML). Their approach is designed to protect healthy cells while specifically targeting and eliminating cancerous cells. This method aims to improve the effectiveness of blood cancer treatments. Vor Biopharma serves patients with blood cancers, their caregivers, and medical professionals in hospitals and oncology centers. What sets Vor Biopharma apart from competitors is their strong emphasis on research and development, investing significantly in scientific research to create a proprietary platform and pipeline of therapies. They generate revenue through partnerships with other pharmaceutical companies and licensing agreements, with the goal of commercializing their therapies after obtaining regulatory approval. The company's mission is to transform the treatment landscape for blood cancers by providing innovative therapies that prioritize patient safety and efficacy.

Cambridge, MassachusettsHeadquarters
2015Year Founded
$147.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Vacation
Parental Leave
401(k) Retirement Plan
401(k) Company Match
Commuter Benefits

Risks

Significant YTD price decline of -62.76% may affect investor confidence.
Key clinical trial data updates are not expected until 2025, causing uncertainty.
Increased competition from companies like Editas Medicine poses potential conflicts.

Differentiation

Vor Bio focuses on protecting healthy cells while targeting cancerous ones.
The company specializes in innovative treatments for blood cancers like AML.
Vor Bio's approach aligns with the rise of personalized medicine.

Upsides

Recent $55.6M funding supports clinical trials and extends cash runway to 2025.
FDA's acceptance of gene therapies may ease approval for Vor Bio's treatments.
Advancements in CRISPR technology enhance precision of Vor Bio's gene editing.

Land your dream remote job 3x faster with AI